Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-7f09c8319207b8e58a7db33f5a93be62",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-7f09c8319207b8e58a7db33f5a93be62",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-7f09c8319207b8e58a7db33f5a93be62",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-7f09c8319207b8e58a7db33f5a93be62\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-7f09c8319207b8e58a7db33f5a93be62</b></p><a name=\"composition-en-7f09c8319207b8e58a7db33f5a93be62\"> </a><a name=\"hccomposition-en-7f09c8319207b8e58a7db33f5a93be62\"> </a><a name=\"composition-en-7f09c8319207b8e58a7db33f5a93be62-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/904/004</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - mirvaso</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/904/004"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp7f09c8319207b8e58a7db33f5a93be62"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - mirvaso",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Mirvaso is and what it is used for</li><li>What you need to know before you use Mirvaso</li><li>How to use Mirvaso</li><li>Possible side effects</li><li>How to store Mirvaso</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What mirvaso is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What mirvaso is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Mirvaso contains the active substance brimonidine which belongs to a group of medicines commonly referred to as alpha agonists . It is applied to the skin of the face to treat redness due to rosacea in adult patients. Redness of the face due to rosacea is caused by high levels of blood flow in the facial skin, which is the result of enlargement (dilation) of the small blood vessels of the skin. When applied, Mirvaso acts to narrow these blood vessels again which reduces the excess blood flow and redness.</p></div>"
}
},
{
"title" : "2. What you need to know before you take mirvaso",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take mirvaso"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"do-not-use-mirvaso\">Do not use Mirvaso:</h2><h2 id=\"if-you-are-allergic-to-brimonidine-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6\">if you are allergic to brimonidine or any of the other ingredients of this medicine (listed in section 6).</h2><h2 id=\"in-children-below-2-years-of-age-as-they-may-be-at-greater-risk-of-side-effects-from-any-of-the-medicine-absorbed-through-the-skin\">in children below 2 years of age, as they may be at greater risk of side effects from any of the medicine absorbed through the skin.</h2><h2 id=\"if-you-are-taking-certain-medicines-used-for-depression-or-parkinson-s-disease-including-so-called-monoamine-oxidase-mao-inhibitors-for-example-selegiline-or-moclobemide-or-tricyclic-antidepressants-such-as-imipramine-or-tetracyclic-antidepressants-such-as-maprotiline-mianserin-or-mirtazapin-use-of-mirvaso-when-taking-these-medicines-may-result-in-a-fall-in-blood-pressure-warnings-and-precautions-talk-to-your-doctor-or-pharmacist-before-using-mirvaso-especially-if\">if you are taking certain medicines used for depression or Parkinson s disease including so-called monoamine oxidase (MAO) inhibitors (for example selegiline or moclobemide) or tricyclic antidepressants (such as imipramine) or tetracyclic antidepressants (such as maprotiline, mianserin or mirtazapin). Use of Mirvaso when taking these medicines may result in a fall in blood pressure. Warnings and precautions Talk to your doctor or pharmacist, before using Mirvaso especially if:</h2><h2 id=\"the-skin-of-your-face-is-irritated-or-has-open-wounds\">the skin of your face is irritated or has open wounds.</h2><h2 id=\"you-have-problems-with-your-heart-or-your-blood-circulation\">you have problems with your heart or your blood circulation.</h2><h2 id=\"you-have-depression-decreased-blood-flow-to-the-brain-or-the-heart-fall-in-blood-pressure-on-standing-up-decreased-blood-flow-to-the-hands-feet-or-skin-or-sj-gren-s-syndrome-a-chronic-disease-in-which-the-body-s-natural-defence---the-immune-system---attacks-the-moisture-producing-glands\">you have depression, decreased blood flow to the brain or the heart, fall in blood pressure on standing up, decreased blood flow to the hands, feet or skin, or Sj gren s syndrome (a chronic disease in which the body s natural defence - the immune system - attacks the moisture-producing glands).</h2><h2 id=\"you-have-kidney-or-liver-problems-or-have-had-them-in-the-past\">you have kidney or liver problems or have had them in the past.</h2><h2 id=\"you-have-had-or-plan-to-have-any-laser-procedure-on-the-skin-of-your-face-it-is-important-to-start-treatment-with-a-small-amount-of-gel-increase-the-dose-gradually-but-do-not-exceed-the-maximum-dose-of-1-gram-approximately-5-pea-sized-amounts-see-also-instructions-how-to-use-mirvaso--do-not-apply-mirvaso-more-than-once-a-day-and-do-not-exceed-the-maximum-daily-dose-of-1gram-approximately-5-pea-sized-amounts-see-also-instructions-how-to-use-mirvaso--worsening-of-skin-redness-flushing-or-burning-feeling-of-the-skin-up-to-1-in-6-patients-experience-the-return-of-their-redness-worse-than-it-was-initially-such-worsening-of-redness-usually-develops-within-the-first-2-weeks-of-treatment-with-mirvaso-generally-it-resolves-spontaneously-after-treatment-is-stopped-the-effect-should-gradually-disappear-within-a-few-days-in-most-cases-before-you-restart-the-treatment-with-mirvaso-test-it-on-a-small-area-of-the-face-on-a-day-when-you-can-stay-at-home-if-you-do-not-experience-worsening-of-redness-or-burning-continue-with-the-usual-treatment-see-section-3-in-case-of-worsening-or-unexpected-redness-discontinue-the-treatment-and-contact-your-doctor-if-any-of-the-above-applies-to-you-talk-to-your-doctor-since-this-medicine-may-not-be-suitable-for-you-children-and-adolescents-do-not-give-this-medicine-to-children-and-adolescents-under-the-age-of-18-years-because-the-safety-and-efficacy-has-not-been-established-for-this-age-group-this-is-particularly-important-in-children-under-the-age-of-2-years-see-do-not-use-mirvaso--other-medicines-and-mirvaso-tell-your-doctor-or-pharmacist-if-you-are-taking-have-recently-taken-or-might-take-any-other-medicines-because-these-medicines-could-affect-your-treatment-with-mirvaso-or-mirvaso-could-affect-your-treatment-with-these-medicines-do-not-take-mirvaso-with-selegiline-moclobemide-imipramine-mianserin-or-maprotiline-which-are-medicines-that-can-be-used-for-depression-or-parkinson-s-disease-as-this-could-lead-to-a-change-in-the-effectiveness-of-mirvaso-or-could-increase-the-chances-for-side-effects-such-as-a-fall-in-blood-pressure-see-under-do-not-use-mirvaso--also-tell-your-doctor-if-you-are-taking-any-of-the-following-medicines\">you have had, or plan to have any laser procedure on the skin of your face. It is important to start treatment with a small amount of gel, increase the dose gradually but do not exceed the maximum dose of 1 gram (approximately 5 pea sized amounts). See also instructions How to use Mirvaso . Do not apply Mirvaso more than once a day and do not exceed the maximum daily dose of 1gram (approximately 5 pea sized amounts). See also instructions How to use Mirvaso . Worsening of skin redness, flushing or burning feeling of the skin Up to 1 in 6 patients experience the return of their redness worse than it was initially. Such worsening of redness usually develops within the first 2 weeks of treatment with Mirvaso. Generally, it resolves spontaneously after treatment is stopped. The effect should gradually disappear within a few days in most cases. Before you restart the treatment with Mirvaso, test it on a small area of the face on a day when you can stay at home. If you do not experience worsening of redness or burning, continue with the usual treatment (see section 3). In case of worsening or unexpected redness, discontinue the treatment and contact your doctor. If any of the above applies to you, talk to your doctor since this medicine may not be suitable for you. Children and adolescents Do not give this medicine to children and adolescents under the age of 18 years because the safety and efficacy has not been established for this age group. This is particularly important in children under the age of 2 years (see Do not use Mirvaso ). Other medicines and Mirvaso Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, because these medicines could affect your treatment with Mirvaso or Mirvaso could affect your treatment with these medicines. Do not take Mirvaso with selegiline, moclobemide, imipramine, mianserin, or maprotiline, which are medicines that can be used for depression or Parkinson s disease, as this could lead to a change in the effectiveness of Mirvaso or could increase the chances for side effects such as a fall in blood pressure (see under Do not use Mirvaso ). Also, tell your doctor if you are taking any of the following medicines:</h2><h2 id=\"medicines-used-for-the-treatment-of-pain-sleep-disorders-or-anxiety-disorders\">medicines used for the treatment of pain, sleep disorders, or anxiety disorders</h2><h2 id=\"medicines-used-for-the-treatment-of-psychiatric-disorders-chlorpromazine-or-used-for-hyperactivity-methylphenidate-or-used-for-high-blood-pressure-reserpine\">medicines used for the treatment of psychiatric disorders (chlorpromazine) or used for hyperactivity (methylphenidate) or used for high blood pressure (reserpine).</h2><h2 id=\"medicines-which-act-on-the-same-body-mechanism-as-mirvaso-other-alpha-agonists-eg-clonidine-so-called-alpha-blockers-or-alpha-antagonists-eg-prazosin-isoprenaline-which-are-most-often-used-for-treatment-of-high-blood-pressure-slow-heart-rate-or-asthma\">medicines which act on the same body mechanism as Mirvaso (other alpha agonists, e.g. clonidine; so-called alpha blockers or alpha antagonists, e.g. prazosin, isoprenaline which are most often used for treatment of high blood pressure, slow heart rate or asthma).</h2><h2 id=\"cardiac-glycosides-eg-digoxin-used-to-treat-heart-problems\">cardiac glycosides (e.g. digoxin), used to treat heart problems.</h2><p>blood pressure lowering medicine such as beta-blockers or calcium channel blockers (e.g. propranolol, amlodipine). If any of the above applies to you, or if you are unsure, talk to your doctor. Mirvaso with alcohol Tell your doctor if you consume alcohol regularly as this could affect your treatment with this medicine. Pregnancy and breast-feeding The use of Mirvaso is not recommended during pregnancy. This is because its effects on your unborn baby are unknown. You should not use this medicine during breast-feeding, as it is unknown whether this medicine passes into the breast milk. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Driving and using machines Mirvaso has no significant influence on the ability to drive and use machines. Mirvaso contains Methylparahydroxybenzoate (E218) which may cause allergic reactions (possibly delayed). This medicine also contains 55 mg propylene glycol (E1520) in each gram which is equivalent to 5.5% w/w, it may cause skin irritation.</p></div>"
}
},
{
"title" : "3. How to take mirvaso",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take mirvaso"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Important: Mirvaso is intended for adults and only for use on the skin of the face. Do not use this medicine on other parts of your body, especially moist body surfaces, e.g. your eyes, mouth, nose or vagina. Do not swallow. Keep Mirvaso gel away from children. How to use Mirvaso Mirvaso is recommended to be applied to the face once a day only. During the first week, start the treatment with a small amount of gel (a pea-sized amount) as explained by your doctor or nurse. If your symptoms remain the same or improve only slightly, you may then gradually increase the amount of gel. Spread it smoothly and evenly as a very thin layer as directed by your doctor or nurse. It is important not to exceed the maximum daily dose of 1gram (5 pea sized amounts applied to the whole face). You should wash your hands immediately after applying this medicine. If your symptoms worsen during treatment with Mirvaso (increased redness, or burning), stop treatment and make an appointment to see your doctor see also section 2 under `Warnings and precautions . You must avoid the eyes, eyelids, lips, mouth, and the inside of the nose. Should any gel get onto these areas, wash them immediately with plenty of water. If you experience worsening of redness or burning you should stop using Mirvaso and contact your doctor if needed. Do not apply any other skin medicines or cosmetics immediately before the daily application of Mirvaso. You should use these products only after the applied Mirvaso has dried. Pay attention when opening the tube / pump for the first time, not to spill a larger quantity of gel than what is needed. If this occurs, you should discard the excess gel so as not to apply more than the recommended dose. See paragraph How to use Mirvaso above. [EU/1/13/904/004-006, EU/1/13/904/008-009] How to open the tube with a child-resistant cap To avoid spilling, do not squeeze the tube while opening or closing. Push down on the cap and turn counterclockwise (turn to the left). Then pull the cap off. How to close the tube with a child-resistant cap Push down and turn clockwise (turn to the right). [EU/1/13/904/007] How to open the pump with a child-resistant cap Push down on the cap and turn counterclockwise (turn to the left) until the cap can be removed. Note: when the cap is removed, the pump is not child-resistant. Before the first use, prime the pump by pressing down several times until the medicine is idispensed onto your fingertip. To apply Mirvaso gel to your face, dispense a pea-sized amount of Mirvaso from the pump onto your fingertip. Continue to press down the pump to get the number of pea sizes you need according to your doctor s prescription (but no more than 5 pea sizes in total). To close the pump, place the cap back on the pump. Push down and turn the cap to the right (clockwise) until it stops. The pump is child-resistant again. If you use more Mirvaso than you should If you use more than the maximum daily dose of 1 gram within a 24 hour period, it could lead to skin irritation or other side effects at the application site. Repeated doses within the same 24 hour period could result in side effects, such as low blood pressure, drowsiness or sleepiness. Please contact your doctor, who will advise you on what action to take. If anyone, especially a child, accidentally swallows Mirvaso, they may have serious side effects and need to be treated in a hospital. Contact your doctor immediately or go to a hospital emergency department right away if you, a child, or anyone else swallows this medicine and has any of these symptoms: feeling dizzy from low blood pressure, vomiting, tiredness or drowsiness, decreased or irregular heartbeats, small pupils (constricted pupils), difficult or slow breathing, floppiness, low body temperature and convulsions (fits). Take the medicine pack with you, so the doctor knows what was swallowed. If you forget to use Mirvaso Mirvaso works on a daily basis, starting with the first day of treatment. If you miss a daily dose, your redness will not be reduced for that day. Do not use a double dose to make up for a forgotten dose and continue your treatment as prescribed. If you stop using Mirvaso A potential consequence of stopping the treatment before finishing the course of treatment is the disease to come back to its initial state. Please contact your doctor before stopping your treatment, so that he could advice a replacement treatment as appropriate. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"like-all-medicines-this-medicine-can-cause-side-effects-although-not-everybody-gets-them-if-you-develop-uncommon-side-effects-of-severe-skin-irritation-or-inflammation-skin-rash-skin-pain-or-discomfort-dry-skin-warm-skin-sensation-tingling-or-sensation-of-pins-and-needles-or-swelling-of-the-face-or-common-side-effects-like-worsening-of-rosacea-discontinue-the-treatment-and-talk-to-your-doctor-since-this-medicine-may-not-be-suitable-for-you-in-some-cases-symptoms-may-extend-beyond-the-treatment-area-see-also-section-2-under-warnings-and-precautions--if-you-develop-contact-allergy-eg-allergic-reaction-rash-or-rare-angioedema-a-serious-allergic-reaction-see-rarely-usually-with-swelling-of-the-face-mouth-or-tongue-stop-using-mirvaso-and-seek-prompt-medical-advice-mirvaso-may-also-cause-the-following-other-side-effects-common-side-effects-may-affect-up-to-1-in-10-people\">Like all medicines, this medicine can cause side effects, although not everybody gets them. If you develop uncommon side effects of severe skin irritation or inflammation, skin rash, skin pain or discomfort, dry skin, warm skin sensation, tingling or sensation of pins and needles or swelling of the face or common side effects like worsening of rosacea, discontinue the treatment and talk to your doctor since this medicine may not be suitable for you. In some cases, symptoms may extend beyond the treatment area. See also section 2 under Warnings and precautions . If you develop contact allergy (e.g. allergic reaction, rash) or rare angioedema (a serious allergic reaction see rarely usually with swelling of the face, mouth or tongue), stop using Mirvaso and seek prompt medical advice. Mirvaso may also cause the following other side effects: Common side effects (may affect up to 1 in 10 people):</h2><h2 id=\"flushing\">flushing</h2><h2 id=\"excessive-whitening-pallor-where-the-gel-is-applied\">excessive whitening (pallor) where the gel is applied</h2><h2 id=\"skin-redness-burning-feeling-of-the-skin-or-itching-uncommon-side-effects-may-affect-up-to-1-in-100-people\">skin redness, burning feeling of the skin or itching Uncommon side effects (may affect up to 1 in 100 people):</h2><h2 id=\"acne\">acne</h2><h2 id=\"dry-mouth\">dry mouth</h2><h2 id=\"feeling-cold-in-hands-and-feet\">feeling cold in hands and feet</h2><h2 id=\"feeling-hot\">feeling hot</h2><h2 id=\"headache\">headache</h2><h2 id=\"nasal-congestion\">nasal congestion</h2><h2 id=\"swelling-of-the-eyelid\">swelling of the eyelid</h2><h2 id=\"urticaria\">urticaria</h2><h2 id=\"dizziness-rare-side-effects-may-affect-up-to-1-in-1000-people\">dizziness Rare side effects (may affect up to 1 in 1000 people):</h2><h2 id=\"hypotension-blood-pressure-decreased\">hypotension (blood pressure decreased)</h2><p>heart rate decrease (slow heart rate, known as bradycardia). Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store mirvaso",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store mirvaso"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton, tube and pump after EXP. The expiry date refers to the last day of that month. This medicine does not require any special storage condition. Store below 30 C and do not freeze. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"what-mirvaso-contains\">What Mirvaso contains</h2><h2 id=\"the-active-substance-is-brimonidine-one-gram-of-gel-contains-33-mg-of-brimonidine-equivalent-to-5-mg-of-brimonidine-tartrate\">The active substance is brimonidine. One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.</h2><p>The other ingredients are carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol (E1520), sodium hydroxide, purified water. See end of section 2 for information on methylparahydroxybenzoate and propylene glycol. What Mirvaso looks like and contents of the pack Mirvaso is a white to light yellow, opaque gel. It is supplied in tubes containing 2, 10 or 30 grams of gel or in airless pump system containing 30 g of gel. Pack size of 1 tube or 1 pump. Not all pack sizes may be marketed. Marketing Authorisation Holder Galderma International Tour Europlaza, 20 avenue Andr Prothin La D fense 4 La D fense Cedex 92France Manufacturer Laboratoires Galderma Z.I. Montd sir 74540 Alby-sur-Ch ran France or Galderma Laboratorium GmbH Toulouser Allee 19a-23a, Pempelfort, Duesseldorf, North Rhine-Westphalia, 40211, Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: sterreich Galderma Austria GmbH Tel: 0043 732 715 e-mail: <a href=\"mailto:austria@galderma.com\">austria@galderma.com</a> Italia Galderma Italia S.p.A. Tel: + 39 337 1176e-mail: <a href=\"mailto:vigilanza@galderma.com\">vigilanza@galderma.com</a> Belgi /Belgique/Belgien Luxembourg/Luxemburg Galderma Benelux BV T l/Tel: +31 183691e-mail: <a href=\"mailto:info.be@galderma.com\">info.be@galderma.com</a> Latvija Tamro SIA, Latvia Tel. +371 67067 PHOENIX PHARMA EOOD, Bulgaria Tel. +359 2 9658 Lietuva Tamro UAB, Lithuania Tel. +37037401 esk republika Slovensk republika 4 LIFE PHARMA CZ, s.r.o. Czech Tel. +420 244 403 e-mail: <a href=\"mailto:Info@4lifepharma.eu\">Info@4lifepharma.eu</a> Magyarorsz g Ewopharma Hungary Kft. Tel.: +36 1 200 4e-mail: <a href=\"mailto:info@ewopharma.hu\">info@ewopharma.hu</a> Danmark Norge sland Suomi/Finland Sverige Galderma Nordic AB Tlf/S mi/Puh/Tel: + 46 18 444 0e-mail: <a href=\"mailto:nordic@galderma.com\">nordic@galderma.com</a> Malta Prohealth Limited Tel. +356 21461851, +356 21460e-mail:<a href=\"mailto:info@prohealth.com.mt\">info@prohealth.com.mt</a> Deutschland Galderma Laboratorium GmbH Tel: + 49 (0) 800 5888e-mail: <a href=\"mailto:patientenservice@galderma.com\">patientenservice@galderma.com</a> Nederland Galderma Benelux BV Tel: + 31 183691e-mail: <a href=\"mailto:info.nl@galderma.com\">info.nl@galderma.com</a> Eesti Tamro Eesti O , Estonia Tel. +372 650 3Polska Galderma Polska Sp. z o.o. Tel.: + 48 22 331 21 e-mail: <a href=\"mailto:info.poland@galderma.com\">info.poland@galderma.com</a></p><p>Pharmassist Ltd : + 30 210 6560Portugal Laboratorios Galderma, SA Sucursal em Portugal Tel: + 351 21 315 19 e-mail: <a href=\"mailto:safety@pharmassist.gr\">safety@pharmassist.gr</a> e-mail: <a href=\"mailto:galderma.portugal@galderma.com\">galderma.portugal@galderma.com</a> Espa a Laboratorios Galderma SA Tel: + 34 902 02 75 e-mail: <a href=\"mailto:RegulatorySpain@galderma.com\">RegulatorySpain@galderma.com</a> Rom nia Neola Pharma SRL Tel: + 40 21 233 17 e-mail: <a href=\"mailto:office.neola@neolapharma.ro\">office.neola@neolapharma.ro</a> France Hrvatska Ireland Slovenija Galderma International T l: +33 08.00.00.99.e-mail: <a href=\"mailto:pharmacovigilance.france@galderma.com\">pharmacovigilance.france@galderma.com</a> United Kingdom (Northern Ireland) Galderma (UK) Ltd. Tel: +44 (0)300 3035e-mail: <a href=\"mailto:medinfo.uk@galderma.com\">medinfo.uk@galderma.com</a> This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site: <a href=\"http://www.ema.europa.eu\">http://www.ema.europa.eu</a>.</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp7f09c8319207b8e58a7db33f5a93be62",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp7f09c8319207b8e58a7db33f5a93be62",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp7f09c8319207b8e58a7db33f5a93be62\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp7f09c8319207b8e58a7db33f5a93be62</b></p><a name=\"mp7f09c8319207b8e58a7db33f5a93be62\"> </a><a name=\"hcmp7f09c8319207b8e58a7db33f5a93be62\"> </a><a name=\"mp7f09c8319207b8e58a7db33f5a93be62-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/904/004</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Mirvaso 3 mg/g gel</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/13/904/004"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "Mirvaso 3 mg/g gel",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
